Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

Erasca, Inc. (ERAS) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

Erasca, Inc. (ERAS), most recent 12 months reported: net loss $287.22M, free cash flow -$98.08M. Latest balance sheet on file: liquid cash $268.74M. From SEC filings. Others in Pharmaceutical Preparations: ENVERIC BIOSCIENCES, INC. · GALMED PHARMACEUTICALS LTD. · EUPRAXIA PHARMACEUTICALS INC. · EQUILLIUM, INC. · Ernexa Therapeutics Inc. · Edgewise Therapeutics, Inc. · FibroBiologics, Inc. · Filana Therapeutics, Inc.

Stock screener

Watchlist